The content on this page was provided by an independent third party and syndicated by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION

The Summit theme “unlocking the $1 Trillion Wealth transfer in Dubai”

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at the Family Office Summit in Dubai with the theme of “Unlocking the $1 Trillion Wealth Transfer in Dubai”.

Panel Discussion Event Details

Date: October 9, 2025
Time: 11:20-11:50 a.m. local time
Location: Park Hyatt, Dubai

The summit will bring together thought leaders, opinion makers, executives and entrepreneurs from around the world to deliberate on unlocking the wealth transfer in Dubai.

Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO, in his presentation, will focus on innovation in biotech/life sciences sector, the role of Artificial intelligence (AI) in drug development as well as the United Arab Emirates (UAE) Genomic project as an untapped differentiator.

Additional information on the Family Office Summit is available on the event website at https://familyofficesummit.ae/dubai/.

Medicus is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:

Carolyn Bonner, President and Acting Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

CTCX Group Launches Two Integrated Powerhouses: CTCX Consulting and CTCX Digital

CTCX Group Launches Two Integrated Powerhouses: CTCX Consulting and CTCX Digital

Bridging the gap between strategy and execution with ONDA™ and Hybrid Organic Growth™ frameworks Oct. 8, 2025 / PRZen / MELBOURNE, Fla. — CTCX Group…

October 9, 2025

Moment of Clarity Expands Outpatient Services in Santa Ana with Specialized Depression Treatment

Moment of Clarity Expands Outpatient Services in Santa Ana with Specialized Depression Treatment

SANTA ANA, CA October 08, 2025 – PRESSADVANTAGE – Moment of Clarity has continued to expand its role as a trusted leader in outpatient mental…

October 9, 2025

MidSolid Challenges Beauty Industry Norms with Launch of High-Performance, pH-Balanced Solid Conditioner Line

MidSolid Challenges Beauty Industry Norms with Launch of High-Performance, pH-Balanced Solid Conditioner Line

HIGHLANDS RANCH, CO October 08, 2025 – PRESSADVANTAGE – MidSolid, an innovator in sustainable personal care, today announced the launch of its new Solid Conditioner…

October 9, 2025

Court King Injury Law Announces Enhanced Legal Service Model Focused on Client Access and Transparency

Court King Injury Law Announces Enhanced Legal Service Model Focused on Client Access and Transparency

October 08, 2025 – PRESSADVANTAGE – Court King Injury Law has announced new operational updates designed to improve client communication, transparency, and accessibility across its…

October 9, 2025

Siam Legal Phuket Expands Support for Those Seeking a Destination Thailand Visa (DTV)

Siam Legal Phuket Expands Support for Those Seeking a Destination Thailand Visa (DTV)

October 08, 2025 – PRESSADVANTAGE – Siam Legal Phuket has expanded its immigration services to meet growing demand from digital nomads and remote workers applying…

October 9, 2025

Chill Squad Air Conditioning Expands Emergency Repair Service Capacity as Demand Grows

Chill Squad Air Conditioning Expands Emergency Repair Service Capacity as Demand Grows

NORTH FORT MYERS, FL October 08, 2025 – PRESSADVANTAGE – Chill Squad Air Conditioning, a leading HVAC contractor serving Fort Myers, Cape Coral, and surrounding…

October 9, 2025

Show Team Pride: American Needle Rolls Out Officially Licensed Colorado Avalanche Apparel

Show Team Pride: American Needle Rolls Out Officially Licensed Colorado Avalanche Apparel

BUFFALO GROVE, IL October 08, 2025 – PRESSADVANTAGE – American Needle, the century-old headwear manufacturer known for its authentic sports merchandise, has expanded its officially…

October 9, 2025

Lone Wolf Exteriors Expands Window and Siding Replacement Services Throughout Texas

Lone Wolf Exteriors Expands Window and Siding Replacement Services Throughout Texas

LEWISVILLE, TX October 08, 2025 – PRESSADVANTAGE – Lone Wolf Exteriors, a Fort Worth-based exterior renovation company, announces the expansion of its residential window and…

October 9, 2025

Executive Base Network Offers Private Office Space Rentals to Meet Growing Demand

Executive Base Network Offers Private Office Space Rentals to Meet Growing Demand

San Ramon, California October 08, 2025 – PRESSADVANTAGE – Executive Base Network, a woman-owned office space provider in San Ramon, California, is expanding its private…

October 9, 2025

Premier Insulation Expands Spray Foam Services to New Markets

Premier Insulation Expands Spray Foam Services to New Markets

Thomasville, GA October 08, 2025 – PRESSADVANTAGE – Premier Insulation, led by owner Levi Glover, announced today the expansion of its spray foam insulation services…

October 9, 2025

Dr. Brannon Claytor Speaks at Brazilian Society of Plastic Surgery Course

Dr. Brannon Claytor Speaks at Brazilian Society of Plastic Surgery Course

BRYN MAWR, PA October 08, 2025 – PRESSADVANTAGE – Dr. R. Brannon Claytor, board-certified plastic surgeon at Claytor Noone Plastic Surgery, served as international faculty…

October 9, 2025

Vanguard Online Marketing Responds to Growing Demand for Digital Visibility With SEO Services

Vanguard Online Marketing Responds to Growing Demand for Digital Visibility With SEO Services

PALMETTO BAY, FL October 08, 2025 – PRESSADVANTAGE – Vanguard Online Marketing, a South Florida-based digital marketing company, has expanded its search engine optimization (SEO)…

October 9, 2025

Ginza Diamond Shiraishi Hong Kong Highlights Commitment to Engagement Ring Craft and Consumer Trends

Ginza Diamond Shiraishi Hong Kong Highlights Commitment to Engagement Ring Craft and Consumer Trends

Causeway Bay, HK October 08, 2025 – PRESSADVANTAGE – Ginza Diamond Shiraishi Hong Kong today announced a continuation of its focus on engagement rings (求婚戒指),…

October 9, 2025

RestoPros of North & Central New Jersey Expands Comprehensive Damage Restoration Services

RestoPros of North & Central New Jersey Expands Comprehensive Damage Restoration Services

MORRISTOWN, NJ October 08, 2025 – PRESSADVANTAGE – RestoPros of North & Central New Jersey has expanded its comprehensive damage restoration services to better serve…

October 9, 2025

Quality Pro Painting Announces Comprehensive Exterior and Interior Services

Quality Pro Painting Announces Comprehensive Exterior and Interior Services

October 08, 2025 – PRESSADVANTAGE – Quality Pro Painting, a Northwest Arkansas painting contractor with over 15 years of industry experience, announces its comprehensive range…

October 9, 2025

AmeriLife’s Next-Generation LeadStar, Powered by EnrollHere, Poised to Drive Unprecedented Success During Medicare’s Annual Enrollment Period

AmeriLife’s Next-Generation LeadStar, Powered by EnrollHere, Poised to Drive Unprecedented Success During Medicare’s Annual Enrollment Period

Platform’s “Better Leads, Better Prices, Better Results” mantra highlights LeadStar’s advanced AI-powered, compliance-integrated tools to empower licensed healthcare agents’ success CLEARWATER, FLORIDA / ACCESS Newswire…

October 9, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission…

October 9, 2025

Calder & Miró: Prints and Drawings, 1967-1976

Calder & Miró: Prints and Drawings, 1967-1976

Kahan Gallery, 922 Madison Avenue, New York MANHATTAN, NY / ACCESS Newswire / October 7, 2025 / Kahan Gallery is pleased to announce Calder &…

October 9, 2025

New to The Street Client Partner Roadzen’s DrivebuddyAI Secures EU General Safety Regulation 2144 Compliance

New to The Street Client Partner Roadzen’s DrivebuddyAI Secures EU General Safety Regulation 2144 Compliance

Becomes the World’s Only Driver Monitoring System Validated Under Both Indian and EU Safety Standards NEW YORK, NY / ACCESS Newswire / October 7, 2025…

October 9, 2025

Global Scams on the Rise: Over Half of Adults Worldwide Report Scam Encounters, 23% Lost Money

Global Scams on the Rise: Over Half of Adults Worldwide Report Scam Encounters, 23% Lost Money

– Global Anti-Scam Alliance and Feedzai Release Global State of Scams 2025 – THE HAGUE, NL / ACCESS Newswire / October 7, 2025 / The…

October 9, 2025

SMX Brings Compliance Into High-Fashion Through Game-Changing CETI Collaboration (NASDAQ:SMX)

SMX Brings Compliance Into High-Fashion Through Game-Changing CETI Collaboration (NASDAQ:SMX)

NEW YORK, NY / ACCESS Newswire / October 7, 2025 / Fashion brands have always been built on one primary characteristic: trust. Trust that the…

October 9, 2025

FundCanna Unveils ReadyPaid(TM) Trusted Partner Network to Drive BNPL Adoption Across the Cannabis Supply Chain

FundCanna Unveils ReadyPaid(TM) Trusted Partner Network to Drive BNPL Adoption Across the Cannabis Supply Chain

Live product demos at this week’s Hall of Flowers in NYC will feature ReadyPaid’s enhanced seller tools, seamless checkout integration, and visibility-driven upgrades for cannabis…

October 9, 2025

Visual Edge IT Strengthens Executive Leadership Team With Key Appointments

Visual Edge IT Strengthens Executive Leadership Team With Key Appointments

NORTH CANTON, OH / ACCESS Newswire / October 7, 2025 / Visual Edge IT today announced the addition of three seasoned executives to its leadership…

October 9, 2025

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

Findings show that Telomir-1 restores the body’s natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A – genes that help block…

October 9, 2025

Horizon Aircraft to Participate in October Conferences

Horizon Aircraft to Participate in October Conferences

TORONTO, ONTARIO / ACCESS Newswire / October 7, 2025 / New Horizon Aircraft (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an…

October 9, 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme “unlocking the $1 Trillion Wealth transfer in Dubai” PHILADELPHIA, PENNSYLVANIA…

October 9, 2025

EMCORE Reintroduces the Industry-Favorite DSP-1750 Fiber Optic Gyroscope with Next-Generation Performance and Design

EMCORE Reintroduces the Industry-Favorite DSP-1750 Fiber Optic Gyroscope with Next-Generation Performance and Design

BUDD LAKE, NJ / ACCESS Newswire / October 7, 2025 / EMCORE LLC, a leading provider of advanced inertial sensors serving the aerospace and defense…

October 9, 2025

The 7 Virtues Launches Buttercream Haze, The Rebel Gourmand

The 7 Virtues Launches Buttercream Haze, The Rebel Gourmand

Brand welcomes new leaders Lori Wachs and Hope Bonneville, grows to 2,100 Sephora doors globally, and debuts its boldest gourmand yet HALIFAX, NS / ACCESS…

October 9, 2025

Engage2Excel Recruitment Solutions Positioned as a Major Contender in Recruitment Process Outsourcing (RPO) Services PEAK Matrix Assessment 2025 – North America

Engage2Excel Recruitment Solutions Positioned as a Major Contender in Recruitment Process Outsourcing (RPO) Services PEAK Matrix Assessment 2025 – North America

MOORESVILLE, NORTH CAROLINA / ACCESS Newswire / October 7, 2025 / Engage2Excel, Inc., an industry-leading provider of recruitment, recognition and engagement solutions, announces, its Recruitment…

October 9, 2025

Alex Honnold to Lead His First-Ever Travel Series, in Partnership With Travel Nevada and Outside

Alex Honnold to Lead His First-Ever Travel Series, in Partnership With Travel Nevada and Outside

Get a Little Out There with Alex Honnold will reveal the hidden stories, unexpected contrasts, and perspective-shifting experiences in his home state RENO, NV /…

October 9, 2025

K 2025 Has A Massive Opportunity to Recognize a Plastics Market Game-Changer: SMX

K 2025 Has A Massive Opportunity to Recognize a Plastics Market Game-Changer: SMX

NEW YORK, NY / ACCESS Newswire / October 7, 2025 / Every three years, the plastics and rubber industry gathers in Düsseldorf, ready to flex….

October 9, 2025

New to The Street Announces 12-Month National Media Partnership with Stardust Power (NASDAQ: SDST)

New to The Street Announces 12-Month National Media Partnership with Stardust Power (NASDAQ: SDST)

NEW YORK CITY, NEW YORK / ACCESS Newswire / October 7, 2025 / New to The Street, one of the nation’s longest- running business television…

October 9, 2025

HotelRunner and Visa Partner Globally to Power Embedded and Autonomous Finance in Travel

HotelRunner and Visa Partner Globally to Power Embedded and Autonomous Finance in Travel

Uniting the strength of Visa’s trusted infrastructure with HotelRunner’s deep presence in hospitality, this strategic preferred partnership sets the foundation for a new era of…

October 9, 2025

Vertosoft and Exclusive Networks Announce Strategic Partnership to Amplify U.S. Public Sector and Commercial Distribution

Vertosoft and Exclusive Networks Announce Strategic Partnership to Amplify U.S. Public Sector and Commercial Distribution

Partnership combines Vertosoft’s public sector distribution and contract access with Exclusive Networks’ commercial distribution and technical services, to accelerate partner & supplier growth LEESBURG, VA…

October 9, 2025

Tidal Wave Auto Spa Surpasses 300 Locations With Grand Openings in South Carolina and Florida

Tidal Wave Auto Spa Surpasses 300 Locations With Grand Openings in South Carolina and Florida

Top Four Conveyor Car Wash Company Celebrates Major Growth Milestone THOMASTON, GA / ACCESS Newswire / October 8, 2025 / Tidal Wave Auto Spa, one…

October 9, 2025

Rolling Stone Leads an Editorial Chorus Spotlighting SMX’s Recycling Platform Mint (NASDAQ: SMX)

Rolling Stone Leads an Editorial Chorus Spotlighting SMX’s Recycling Platform Mint (NASDAQ: SMX)

NEW YORK, NY / ACCESS Newswire / October 8, 2025 / Every so often, culture catches up to innovation – and Rolling Stone was first…

October 9, 2025

Recycling Rules Without Proof Are Just Non-Negotiable Paper; SMX Turns Them Into Tradable Currency (NASDAQ: SMX)

Recycling Rules Without Proof Are Just Non-Negotiable Paper; SMX Turns Them Into Tradable Currency (NASDAQ: SMX)

NEW YORK, NY / ACCESS Newswire / October 8, 2025 / Decades of climate conferences and sustainability summits have produced mountains of pledges and pages…

October 9, 2025

Huntington Learning Center Russellville Highlights New NAEP Data

Huntington Learning Center Russellville Highlights New NAEP Data

Russellville, AR October 08, 2025 –(PR.com)– The NCES report (https://www.nationsreportcard.gov) reveals continued national declines in student performance in science, reading, and mathematics. According to NPR…

October 9, 2025

The SIM Card Attack No One’s Ready For – And the SMX Technology That Can Stop It (NASDAQ: SMX)

The SIM Card Attack No One’s Ready For – And the SMX Technology That Can Stop It (NASDAQ: SMX)

NEW YORK, NY / ACCESS Newswire / October 8, 2025 / History is full of moments when the world came dangerously close to catastrophe, not…

October 9, 2025

Edward J. Beltran and Fierce Inc. Introduce Ethical Biometric Intelligence, Redefining the Future of Work

Edward J. Beltran and Fierce Inc. Introduce Ethical Biometric Intelligence, Redefining the Future of Work

SEATTLE, WA / ACCESS Newswire / October 8, 2025 / Edward J. Beltran, CEO of Fierce Inc. and best-selling author of “Fierce Resilience,” today announced…

October 9, 2025